DK0804479T3 - Fremgangsmåde til behandling af diabetes mellitus ved anvendelse af KGF - Google Patents

Fremgangsmåde til behandling af diabetes mellitus ved anvendelse af KGF

Info

Publication number
DK0804479T3
DK0804479T3 DK95934808T DK95934808T DK0804479T3 DK 0804479 T3 DK0804479 T3 DK 0804479T3 DK 95934808 T DK95934808 T DK 95934808T DK 95934808 T DK95934808 T DK 95934808T DK 0804479 T3 DK0804479 T3 DK 0804479T3
Authority
DK
Denmark
Prior art keywords
kgf
diabetes mellitus
treating diabetes
mammals
pharmaceutical compositions
Prior art date
Application number
DK95934808T
Other languages
English (en)
Inventor
Sharon Lea Aukerman
Glenn Francis Pierce
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DK0804479T3 publication Critical patent/DK0804479T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1825Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/50Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK95934808T 1994-10-13 1995-10-12 Fremgangsmåde til behandling af diabetes mellitus ved anvendelse af KGF DK0804479T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32347594A 1994-10-13 1994-10-13
US32334094A 1994-10-13 1994-10-13
US48782595A 1995-06-07 1995-06-07
PCT/IB1995/000992 WO1996011950A1 (en) 1994-10-13 1995-10-12 Method of treating diabetes mellitus using kgf

Publications (1)

Publication Number Publication Date
DK0804479T3 true DK0804479T3 (da) 2007-01-29

Family

ID=27406268

Family Applications (2)

Application Number Title Priority Date Filing Date
DK95934808T DK0804479T3 (da) 1994-10-13 1995-10-12 Fremgangsmåde til behandling af diabetes mellitus ved anvendelse af KGF
DK95934793T DK0785948T3 (da) 1994-10-13 1995-10-12 Analoger af keratinocyt vækstfaktor

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK95934793T DK0785948T3 (da) 1994-10-13 1995-10-12 Analoger af keratinocyt vækstfaktor

Country Status (23)

Country Link
EP (2) EP0785948B1 (da)
JP (2) JP4216329B2 (da)
KR (1) KR100278597B1 (da)
CN (1) CN1168678A (da)
AT (2) ATE342278T1 (da)
AU (1) AU3707795A (da)
BG (2) BG101392A (da)
BR (2) BR9509269A (da)
CA (2) CA2202075C (da)
CZ (3) CZ297329B6 (da)
DE (2) DE69530403T2 (da)
DK (2) DK0804479T3 (da)
EE (2) EE03975B1 (da)
ES (2) ES2196082T3 (da)
FI (2) FI971420A0 (da)
HU (2) HUT78050A (da)
NO (2) NO971566L (da)
NZ (2) NZ505502A (da)
PL (2) PL182888B1 (da)
PT (2) PT785948E (da)
SI (2) SI0785948T1 (da)
SK (2) SK284534B6 (da)
WO (2) WO1996011949A2 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2153816T3 (es) 1989-01-31 2001-03-16 Jeffrey S Rubin Adn que codifica un factor de crecimiento especifico contra celulas epiteliales.
US7084119B2 (en) 1993-06-29 2006-08-01 Chiron Corporation Truncated keratinocyte growth factor (KGF) having increased biological activity
KR960703433A (ko) 1993-06-29 1996-08-17 로버트 피. 블랙버언 증가된 생물학적 활성을 갖는 끝이 잘린 케라틴세포성장인자(kgf) (a truncated keratinocyte growth factor(kgf) having increased biological activity)
IL115605A (en) * 1994-10-13 2003-06-24 Amgen Inc Method for purifying keratinocyte growth factors
US7232667B2 (en) 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US6077692A (en) 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
DE69603269T3 (de) * 1995-04-27 2007-02-22 Coöperatie Cosun U.A. Derivate von inulin
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
DK0935652T3 (da) * 1996-10-15 2004-07-26 Amgen Inc Keratinocyt vækstfaktor-2 produkter
EP1473366A1 (en) * 1996-10-15 2004-11-03 Amgen Inc. Keratinocyte growth factor-2 products
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
US7153943B2 (en) 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
ATE375363T1 (de) 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
WO1999032135A1 (en) 1997-12-22 1999-07-01 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
US6242666B1 (en) * 1998-12-16 2001-06-05 The Scripps Research Institute Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
BR122013003013B8 (pt) * 1999-01-14 2021-07-06 Bolder Biotechnology Inc proteína isolada monopeguilada do hormônio do crescimento e método para sua obtenção
US6248725B1 (en) 1999-02-23 2001-06-19 Amgen, Inc. Combinations and methods for promoting in vivo liver cell proliferation and enhancing in vivo liver-directed gene transduction
CA2437270A1 (en) * 2001-02-06 2002-08-15 Merck Patent Gesellschaft Mit Beschraenkter Haftung Modified keratinocyte growth factor (kgf) with reduced immunogenicity
JP2005500390A (ja) 2001-08-21 2005-01-06 カイロン コーポレイション Kgfポリペプチド組成物
AU2007214362B2 (en) * 2001-08-21 2009-11-26 Novartis Vaccines And Diagnostics, Inc. KGF polypeptide compositions
US8304387B2 (en) 2004-12-15 2012-11-06 Swedish Orphan Biovitrum Ab (Publ) Therapeutic formulations of keratinocyte growth factor
CN102242124B (zh) * 2010-05-10 2013-05-22 齐鲁制药有限公司 改造的角化细胞生长因子基因及其在酵母中的表达
KR102440312B1 (ko) * 2020-08-28 2022-09-05 한국해양과학기술원 온도안정성을 향상시킨 fgf7 폴리펩타이드 및 그 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
JPH01137994A (ja) * 1987-08-10 1989-05-30 Shionogi & Co Ltd reg蛋白質
US5145225A (en) * 1988-07-27 1992-09-08 Muller George M Carpet stretcher
ES2153816T3 (es) * 1989-01-31 2001-03-16 Jeffrey S Rubin Adn que codifica un factor de crecimiento especifico contra celulas epiteliales.
JP3303211B2 (ja) * 1991-04-26 2002-07-15 武田薬品工業株式会社 bFGFムテインおよびその製造法
JP3578761B2 (ja) * 1993-03-26 2004-10-20 アムジエン・インコーポレーテツド 表皮ケラチン細胞成長因子の治療目的での使用
US5348563A (en) * 1993-06-29 1994-09-20 Honeywell Inc. Air purifying apparatus
KR960703433A (ko) * 1993-06-29 1996-08-17 로버트 피. 블랙버언 증가된 생물학적 활성을 갖는 끝이 잘린 케라틴세포성장인자(kgf) (a truncated keratinocyte growth factor(kgf) having increased biological activity)
GB9315501D0 (en) * 1993-07-27 1993-09-08 Ici Plc Surfactant compositions
AU7475694A (en) * 1993-08-02 1995-02-28 Prizm Pharmaceuticals, Inc. Monogenous preparations of cytotoxic conjugates

Also Published As

Publication number Publication date
SK43197A3 (en) 1999-03-12
CA2201940C (en) 2009-05-12
PL182888B1 (pl) 2002-03-29
FI971420A7 (fi) 1997-04-04
NO971566D0 (no) 1997-04-04
SK45597A3 (en) 1999-02-11
EP0785948A1 (en) 1997-07-30
JP4216329B2 (ja) 2009-01-28
FI971536L (fi) 1997-06-09
WO1996011949A3 (en) 1996-12-12
BG63167B1 (bg) 2001-05-31
CZ297328B6 (cs) 2006-11-15
AU681546B2 (en) 1997-08-28
FI971536A0 (fi) 1997-04-11
AU3708395A (en) 1996-05-06
DE69535264T2 (de) 2007-02-01
JPH10507080A (ja) 1998-07-14
FI120040B (fi) 2009-06-15
BR9509269A (pt) 1997-12-23
BR9509329A (pt) 1997-10-14
SI0785948T1 (en) 2003-08-31
NZ335109A (en) 2000-08-25
CZ297329B6 (cs) 2006-11-15
FI971420L (fi) 1997-04-04
EE9700081A (et) 1997-10-15
HUT78058A (hu) 1999-07-28
ATE237633T1 (de) 2003-05-15
CZ98197A3 (cs) 1998-11-11
NO971568D0 (no) 1997-04-04
CA2202075C (en) 2003-12-09
KR100278597B1 (ko) 2001-01-15
EP0785948B1 (en) 2003-04-16
DE69530403T2 (de) 2003-10-30
WO1996011949A2 (en) 1996-04-25
PL319784A1 (en) 1997-08-18
EP0804479A1 (en) 1997-11-05
ES2196082T3 (es) 2003-12-16
EE9700225A (et) 1998-02-16
DK0785948T3 (da) 2003-08-04
HUT78050A (hu) 1999-07-28
HU226168B1 (en) 2008-05-28
JP4426646B2 (ja) 2010-03-03
CA2202075A1 (en) 1996-04-25
BG101408A (bg) 1997-12-30
EP0804479B1 (en) 2006-10-11
WO1996011950A1 (en) 1996-04-25
JPH10507193A (ja) 1998-07-14
DE69535264D1 (de) 2006-11-23
AU3707795A (en) 1996-05-06
ATE342278T1 (de) 2006-11-15
EE03975B1 (et) 2003-02-17
PT785948E (pt) 2003-09-30
SK284534B6 (sk) 2005-06-02
NO971568L (no) 1997-06-12
NO318761B1 (no) 2005-05-02
PT804479E (pt) 2007-02-28
FI971420A0 (fi) 1997-04-04
BG101392A (en) 1997-10-31
SI0804479T1 (sl) 2006-12-31
NO971566L (no) 1997-04-14
CA2201940A1 (en) 1996-04-25
ES2273338T3 (es) 2007-05-01
CZ105097A3 (cs) 1998-10-14
PL320484A1 (en) 1997-09-29
NZ505502A (en) 2005-01-28
DE69530403D1 (de) 2003-05-22
CN1168678A (zh) 1997-12-24

Similar Documents

Publication Publication Date Title
DK0804479T3 (da) Fremgangsmåde til behandling af diabetes mellitus ved anvendelse af KGF
DK0861666T3 (da) Farmakologisk præparat til anvendelse ved behandling af diabetes
FI953180A7 (fi) Sokeritaudin komplikaatioiden hoitamiseen tarkoitetut koostumukset
ATE249421T1 (de) Inhibitoren der alpha4-beta1 vermittelten zelladhäsion
DE69603089D1 (de) Zusammensetzung zur behandlung von mauerwerk
DK0755258T3 (da) Fremgangsmåde til behandling af sygdom ved at anvende Sertoli-celler og allo-transplantater eller xeno-transplantater
ATE190623T1 (de) Verwendung von steroiden zur inhibierung von angiogenesis
FI990171L (fi) Uusia yhdisteitä ja koostumuksia tryptaasiaktiivisuuden liittyvien tautien hoitamiseksi
AU2209500A (en) Inhibitors of alpha4beta1 mediated cell adhesion
MD960168A (ro) Metodă şi compuşi pentru tratamentul infecţiilor virale
EP0711159A4 (en) METHODS AND COMPOSITIONS FOR TREATING ASTHMA, ATHEROSCLEROSIS AND INFLAMMATORY DISEASE USING OPTICALLY PURE (-) - ZILEUTON
NO975488L (no) Anvendelse av pyrrolidinderivater ved behandling av alkoholisme
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
DE69110861D1 (de) Mittel zur verbesserung des kollagenmetabolismus und dessen verwendung.
DE59611353D1 (de) Transketolase-verwandtes protein
DK17491D0 (da) Sugeindretning til anvendelse ved tandbehandling
NO912200L (no) Behandling av problemavfalls-materiale.